Report in English with a Dutch summary (KCE reports 45A)

KCE reports vol.45 Screening for Colorectal Cancer 229
217. Friedman LC, Everett TE, Peterson L, Ogbonnaya KI, Mendizabal V. Compliance with
fecal occult blood test screening among low-income medical outpatients: a
randomized controlled trial using a videotaped intervention. Journal of Cancer
Education. 2001;16(2):85-8.
218. Federici A, Giorgi Rossi P, Bartolozzi F, Farchi S, Borgia P, Guastcchi G. The role of
GPs in increasing compliance to colorectal cancer screening: a randomised
controlled trial (Italy). Cancer Causes & Control. 2006;17(1):45-52.
219. Kerr J, Broadstock, M., Day, P., Hogan, S. Effectiveness and cost-effectiveness of
population screening for colorectal cancer : a systematic review of the literature.
New Zealand Health Technology Assessment; 2005 May 2005. Volume 8Number 1
220. NZGG, Cancer NHCWPoPSfC. Recommendations on population screening for
colorectal cancer in New Zealand. New Zealand Medical Journal. 1999;112(1080):4-
6.
221. Halligan S, Altman DG, Taylor SA, Mallett S, Deeks JJ, Bartram CI, et al. CT
colonography in the detection of colorectal polyps and cancer: systematic review,
meta-analysis, and proposed minimum data set for study level reporting. Radiology.
2005;237(3):893-904.
222. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic
colonography. Annals of Internal Medicine. 2005;142(8):635-50.
223. Johnson PM, Gallinger S, McLeod RS. Surveillance colonoscopy in individuals at risk
for hereditary nonpolyposis colorectal cancer: An evidence-based review. Diseases
of the Colon and Rectum. 2006;49(1):80-93.
224. Hassan C, Zullo A, Risio M, Rossini FP, Morini S. Histologic risk factors and clinical
outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum.
2005;48(8):1588-96.
225. Chen S, Watson P, Parmigiani G. Accuracy of MSI testing in predicting germline
mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic
tests without a gold standard. Biostatistics. 2005;6(3):450-64.
226. Ewald N, Toepler M, Akinci A, Kloer HU, Bretzel RG, Hardt PD. Pyruvate kinase M2
(tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current
published data. Zeitschrift fur Gastroenterologie. 2005;43(12):1313-7.
227. Lin OS, Gerson LB, Soon M-S, Schembre DB, Kozarek RA. Risk of proximal colon
neoplasia with distal hyperplastic polyps: a meta-analysis. Archives of Internal
Medicine. 2005;165(4):382-90.
228. Federici A, Borgia P, Guasticchi G. Evidence-based planning: the case of colorectal
cancer mass-screening in the Latium region-Italy. Ann Ig. 2005;17(4):313-22.
229. Ferreira MR, Dolan NC, Fitzgibbon ML, Davis TC, Gorby N, Ladewski L, et al.
Health care provider-directed intervention to increase colorectal cancer screening
among veterans: results of a randomized controlled trial. J Clin Oncol.
2005;23(7):1548-54.
230. Walsh JME, Salazar R, Terdiman JP, Gildengorin G, Perez-Stable EJ. Promoting use of
colorectal cancer screening tests. Can we change physician behavior? Journal of
General Internal Medicine. 2005;20(12):1097-101.
231. Forbes GM, Edwards JT, Foster NM, Wood CJ, Mendelson RM. Randomized single
blind trial of two low-volume bowel preparations for screening computed
tomographic colonography. Abdominal imaging. 2005;30(1):48-52.
232. Summers RM, Yao J, Pickhardt PJ, Franaszek M, Bitter I, Brickman D, et al.
Computed tomographic virtual colonoscopy computer-aided polyp detection in a
screening population. Gastroenterology. 2005;129(6):1832-44.
233. Moore LE, Huang W-Y, Chatterjee N, Gunter M, Chanock S, Yeager M, et al.
GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal
adenoma. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(7):1823-7.